Introduction

The clinical success of adoptive T cell transfer therapy is resulting in growing enthusiasm as indicated by the ever-increasing number of clinical trials and the involvement of large pharmaceutical companies. Aiming to streamline the safe and robust clinical manufacturing of gene-engineered T cells, we have developed a GMP-compliant stimulation reagent, MACS® GMP T Cell TransAct™. This reagent enables potent polyclonal T cell activation prior to gene modification (transfection and transduction) in the absence of feeder cells and can be easily integrated into a closed manufacturing process such as the TCT Process on the ClinMACS Prodigy.

Results

1. TransAct™ T Cell Reagent enables potent T cell stimulation, proliferation, and expansion in research settings

2. Clinical-scale manufacturing of gene-modified T cells

Conclusion

- MACS GMP T Cell TransAct™ enables potent and robust T cell activation.
- The reagent can be used in combination with the commercially available TCT Process on the ClinMACS Prodigy.
- The automated process for manufacturing gene-modified T cells yields a consistent cell product for the development of adoptive T cell therapies.

Funding: This project has received funding from the European Union’s Horizon 2020 research and innovation programme under grant agreement No 667980.

Daniela Mauer, Carola Barth, Katharina Drechsel, Carsten Reude, Ian C. D. Johnston, Stefan Wild, Sabrina Schmitz, Carolin Kolbe, Mario Assenmacher, Andrew D. M. Kaiser, and Nadine Mockel-Tenbrinck

Miltenyi Biotec GmbH, Bergisch Gladbach, Germany